Last reviewed · How we verify
Normal saline + Standard Treatment
Normal saline provides isotonic fluid replacement and maintains electrolyte balance as a supportive therapy alongside standard treatment.
Normal saline provides isotonic fluid replacement and maintains electrolyte balance as a supportive therapy alongside standard treatment. Used for Supportive care in phase 3 clinical trials (specific indication unknown without trial protocol).
At a glance
| Generic name | Normal saline + Standard Treatment |
|---|---|
| Also known as | Vehicle |
| Sponsor | Pharmazz, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Normal saline (0.9% sodium chloride) is a physiologic solution that restores intravascular volume and maintains osmotic balance without altering serum electrolyte concentrations. It serves as a foundational supportive care component in clinical trials, typically used to ensure adequate hydration and perfusion while the investigational or standard therapeutic agent exerts its primary effect.
Approved indications
- Supportive care in phase 3 clinical trials (specific indication unknown without trial protocol)
Common side effects
- Hyperchloremic acidosis
- Fluid overload
- Hypokalemia
Key clinical trials
- Endorotor Resection In Refractory Barrett's Dysplasia Patients (NA)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease (NA)
- Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery (NA)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Normal saline + Standard Treatment CI brief — competitive landscape report
- Normal saline + Standard Treatment updates RSS · CI watch RSS
- Pharmazz, Inc. portfolio CI